Search

University of California MOG Peptide Glioblastoma Patent Application

The Regents of the University of California published European patent application EP4054596A1 on April 15, 2026, covering the use of MOG peptide for priming glioblastoma treatment. The application names six inventors and includes ten IPC classifications spanning peptide sequences, cancer therapeutics, and cellular immunotherapies across 31 designated contracting states.